Cardiovascular risk in uremic patients: darkness after AURORA.
Robles
N R
NR
University of Salamanca School of Medicine, Salamanca, Spain. nroblesp@senefro.org
Macias
J F
JF
D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003627:Data Interpretation, Statistical; D005464:Fluorobenzenes / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D008055:Lipids / Q000097:blood; D010352:Patient Dropouts / Q000706:statistics & numerical data; D018579:Patient Selection; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis / Q000009:adverse effects*; D012107:Research Design; D012306:Risk; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D014511:Uremia / Q000097:blood / Q000188:drug therapy* / Q000401:mortality
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium